The study, involving 300 acutely ill adults treated at four US hospitals, examined whether autonomous oxygen titration could improve the amount of time patients spent with peripheral oxygen saturation, or SpO₂, between 90% and 96%. This range, described as targeted normoxemia, was compared with the period patients spent in hypoxemia, defined in the trial as an SpO₂ below 88%. The investigators found that autonomous oxygen titration increased time in the target range and reduced time spent below it compared with usual clinical care.

Oxygen saturation is commonly measured using a pulse oximeter, a small sensor typically placed on a patient’s finger. The device estimates the percentage of hemoglobin carrying oxygen by analyzing how light passes through tissue. Although the measurement is not perfect and can be affected by motion, poor circulation, skin pigmentation, and other factors, continuous pulse oximetry gives clinicians a rapidly updated view of a patient’s oxygen status.

In ordinary hospital care, oxygen administration often depends on intermittent adjustments by nurses, respiratory therapists, or physicians. A patient’s oxygen requirement can change quickly as breathing worsens, improves, or fluctuates with movement and treatment. Between clinical checks, patients may therefore receive more oxygen than necessary or less than needed. The result can be prolonged exposure to levels outside the intended target, even when staff are providing appropriate care under demanding conditions.

Autonomous oxygen titration is designed to make these adjustments continuously. In principle, a computer-controlled system receives oxygen saturation readings and automatically changes the amount of supplemental oxygen delivered through a device such as a nasal cannula or face mask. If saturation falls toward or below the lower limit, the system can increase oxygen delivery. If saturation rises above the target range, it can reduce the flow, helping prevent unnecessary oxygen exposure.

The approach addresses a longstanding tension in acute care: clinicians must correct hypoxemia promptly while avoiding excessive oxygen administration. Oxygen is essential for cellular metabolism, but high concentrations or prolonged exposure can have undesirable physiological effects, depending on a patient’s condition. Excess oxygen may contribute to oxidative stress and can complicate the management of certain respiratory and cardiovascular disorders. At the same time, aggressively reducing oxygen in a patient who is deteriorating could be dangerous. An automated system must therefore respond rapidly while remaining within carefully defined safety boundaries.

In this trial, the autonomous system safely increased the proportion of time patients spent in the 90%-to-96% normoxemia range. It also decreased the proportion of time they experienced oxygen saturation below 88%. The findings suggest that automation may improve the consistency of oxygen treatment, not by replacing clinical judgment, but by handling frequent, small adjustments that are difficult to perform manually around the clock.

The results are particularly relevant in hospitals, where oxygen is among the most frequently used therapies and where staff must monitor many patients simultaneously. A system that can continuously respond to changing oxygen needs could reduce the burden of routine titration and potentially standardize care across shifts and clinical settings. It may also be useful in emergency departments, inpatient wards, and other environments where acutely ill adults are monitored with continuous pulse oximetry.

However, the technology does not eliminate the need for medical oversight. Pulse oximetry is an indirect measurement, and a displayed saturation value must always be interpreted alongside respiratory rate, work of breathing, blood gas measurements when appropriate, mental status, circulation, and the underlying diagnosis. Automated oxygen delivery also requires safeguards for sensor failure, abrupt clinical deterioration, disconnection of tubing, and situations in which a patient’s target saturation should differ from the general range used in the trial.

The researchers will present the findings at the Military Health System Research Symposium. The study is associated with JAMA Internal Medicine and carries the digital object identifier 10.1001/jamainternmed.2026.4023. If confirmed in additional populations and clinical environments, autonomous oxygen titration could become an important example of how carefully designed automation helps transform a basic therapy into a more responsive and precise treatment. For now, the trial provides evidence that a machine-guided approach can keep acutely ill adults closer to a desired oxygen range while reducing episodes of hypoxemia under real-world hospital care.

Subject of Research: Autonomous oxygen titration for acutely ill adults receiving supplemental oxygen

Web References: https://mhsrs.health.mil/MHSRS/ ; https://doi.org/10.1001/jamainternmed.2026.4023

References: Douin DJ, Ginde AA, et al. Randomized clinical trial of autonomous oxygen titration in acutely ill adults. JAMA Internal Medicine. doi:10.1001/jamainternmed.2026.4023

Keywords: autonomous oxygen titration, supplemental oxygen, oxygen saturation, normoxemia, hypoxemia, pulse oximetry, artificial intelligence in medicine, automated clinical care, acute illness, randomized clinical trial, hospital medicine, respiratory care

Prof. Vasilev’s journey into this area of research was sparked by a personal experience with peppermint leaves, which provided relief for his sore throat when added to his drink. This observation prompted him to investigate whether the bioactive properties of peppermint could be effectively transformed into a durable, protective coating for medical devices through plasma technology. His expertise, accumulated over two decades of research, laid the groundwork for this novel approach.

The research team, including several prominent scientists, carried out their work in the Biomedical Nanoengineering Laboratory at Flinders University. This collaboration included Professor Vasilev, Associate Professor Vi-Khanh Truong, Dr. Andrew Hayes, and two dedicated PhD candidates, Trong Quan Luu and Tuyet Pham. Together, they created a nanoscale peppermint-oil coating that not only protects against various forms of infection but also offers anti-inflammatory and antioxidant benefits, crucial for maintaining compatibility with human tissue.

The methodology employed by the researchers involved the use of atmospheric pressure plasma, a cutting-edge technique that allowed them to turn peppermint essential oil into an ultra-thin film capable of tightly adhering to a diverse array of medical materials. This plasma-induced polymerization is a pivotal aspect of the coating process, circumventing the need for heat or harmful chemicals, which is often a limitation in other coating methods. By preserving the natural characteristics of the peppermint oil, the researchers have developed a coating that remains effective while ensuring environmental sustainability.

An important milestone in the project’s development was the testing of this innovative coating on urinary catheters, medical devices that have frequently been associated with healthcare-associated infections. As co-author Associate Professor Truong points out, such infections significantly contribute to patient discomfort and increased healthcare costs. The results revealed that the peppermint coating effectively eliminated up to 90% of harmful reactive oxygen species, mitigating tissue damage and irritation.

More impressive still, the coating displayed a strong antibacterial effect against critical pathogens, including Escherichia coli and Pseudomonas aeruginosa. It was found to kill bacteria on contact without releasing any pharmaceutical drugs into the body, which can often present a risk of adverse effects. Furthermore, the peppermint oil coating was shown to enhance bacterial sensitivity to conventional antibiotics, which could play a crucial role in combating antibiotic resistance—a mounting challenge in contemporary healthcare.

The findings from Dr. Andrew Hayes indicated that the peppermint coating modulates the immune response, reducing pro-inflammatory signals while enhancing those associated with healing. This phenomenon aids the body in tolerating medical devices more comfortably, reflecting a critical advancement in how we can improve patient experiences with medical interventions.

Laboratory testing further validated the safety of the coating for human tissue, demonstrating that human cells could grow normally on its surface while maintaining metabolic health. This compatibility creates a strong foundation for the coating’s application to various medical devices, such as those used in orthopedic surgery and long-term clinical care settings.

In addition to its healthcare benefits, the technological process intrinsic to developing this coating aligns with environmentally conscious manufacturing practices. By utilizing renewable peppermint oil and eschewing solvent-based methods, the researchers have crafted a system that has the potential to be powered entirely by renewable sources, marking significant progress in the pursuit of sustainable medical technologies.

The proximity of the Biomedical Nanoengineering Laboratory to Flinders Medical Centre has facilitated productive collaborations between researchers, medical professionals, and nursing staff. These partnerships ensure that the research is clinically relevant, tailored to real-world applications, and ultimately beneficial for patient care.

Moving forward, the team hopes their work will stimulate the advent of a new class of medical coatings that leverage natural compounds to enhance safety outcomes for patients. Their innovative spirit positions them at the forefront of transformational research in biomedical engineering, driven by a commitment to improving patient outcomes.

Ultimately, the researchers at Flinders University are eager to continue developing their peppermint-based technology and are actively seeking opportunities for collaboration with industry partners. Their aim is to transition their findings from the lab to real-world applications, wherein patients can benefit from this exceptional advancement in medical coatings.

In conclusion, the development of a peppermint essential oil coating signifies a remarkable stride towards safer medical devices, aligning natural remedies with cutting-edge biomedical technology. As the study progresses, the implications for increased patient comfort and infection prevention could redefine medical practices, opening up avenues for future research and applications.

Subject of Research: Human tissue samples
Article Title: A Multifunctional Bioactive Nanoscale Coating Deposited by Atmospheric Pressure Plasma Polymerization of Peppermint Essential Oil
News Publication Date: 19-Jan-2026
Web References: DOI link
References: Published in the journal Small
Image Credits: Flinders University

Keywords

Antibacterial coating, peppermint essential oil, plasma technology, medical devices, infection prevention, inflammation, biomedical engineering, human tissue compatibility, sustainable manufacturing, antibiotic resistance

At the core of Mayo Clinic Platform_Orchestrate lies a unique confluence of advanced technology, clinical data, and expert knowledge. This program grants collaborators streamlined access to Mayo Clinic’s extensive repository of de-identified clinical data, harnesses the power of artificial intelligence tools, and taps into the expertise of physician-scientists. The aim of this intricate infrastructure is explicit: to facilitate a smoother, more efficient pathway from discovery to deployment of new therapeutics in a clinical setting.

What sets Mayo Clinic Platform_Orchestrate apart is its strategic positioning as a collaborative entry point within Mayo Clinic’s broader ecosystem. The platform functions as a conduit for biopharma and medical device companies, allowing them to tap into real-world clinical data and biospecimens essential for novel discoveries. In an age where data drives innovation, the access provided through this program is crucial for validating theories, refining product offerings, and ultimately deploying solutions that significantly impact patient lives.

Maneesh Goyal, Mayo Clinic’s chief operating officer for the Platform division, emphasized the significance of this initiative, stating that the aim is to empower life sciences partners to expedite the safe delivery of new therapies to patients. By amalgamating trusted clinical data with cutting-edge artificial intelligence, Mayo Clinic is not merely adapting to the evolving landscape of medical technology; rather, it is actively redefining the potential of clinical development. This initiative represents a bold step towards settling the longstanding tension between innovation speed and thorough validation.

The program outlines three primary phases of collaboration: Discovery, Validation, and Deployment. Within the Discovery phase, companies gain access to a treasure trove of longitudinal clinical data and associated biospecimens. This element is vital for generating new insights that feed into the innovation cycle. As organizations navigate the intricate pathways of clinical development, the availability of multi-modal data enables them to explore various angles in patient care, leading to the identification of potentially groundbreaking therapeutic strategies.

Within the Validation phase, the use of rigorous testing for artificial intelligence models signifies a commitment to precision and accuracy. Companies are enabled to validate their digital solutions thoroughly, ensuring that their outputs meet the high standards required for adoption in clinical settings. The integration of AI into healthcare settings is often fraught with challenges, but the Mayo Clinic Platform_Orchestrate initiative provides the necessary infrastructure to shepherd companies through these hurdles, affirming the critical role data plays in substantiating innovation.

The Deployment phase pits innovative solutions against the real-world dynamics of healthcare practice, leveraging the scalable infrastructure offered by Mayo Clinic. By ensuring that new technologies are seamlessly integrated across both domestic and international settings, the potential for widespread impact on healthcare delivery increases exponentially. The alignment of innovation with practical application is essential for any medical breakthrough to take root, and this program stands as a model for future endeavors in clinical setup.

Notably, several high-profile partnerships have already sprung forth from the Mayo Clinic Platform_Orchestrate initiative, underscoring the burgeoning interest from life sciences and technology firms. Early projects are already yielding promising results, including the development of multimodal AI models that facilitate early disease detection and the creation of advanced tools for accurately identifying patients who could benefit from targeted therapies. These initiatives reflect the synergy between clinical insight and technological advancement that is central to the mission of Mayo Clinic Platform_Orchestrate.

Additionally, the program is designed to enhance clinical trial recruitment efforts, which have historically been a bottleneck in the therapeutic development cycle. By diversifying and streamlining recruitment processes, companies can implement strategies that ensure a broader and more representative participant base, ultimately leading to more robust trial outcomes. This multifaceted approach exemplifies the initiative’s overarching goal: making the path from innovation to clinical application shorter and more efficient.

As healthcare continues to undergo rapid transformation thanks to advancements in technology, the role of data is becoming increasingly prominent. Mayo Clinic Platform_Orchestrate acknowledges this paradigm shift and leverages its resources to keep pace with evolving expectations. The coupling of rich, de-identified clinical data provided by nference, a prominent player in healthcare data and AI, guides partners in making informed decisions, optimizing clinical trial designs, and enhancing overall patient management throughout the therapy lifecycle.

In an era where healthcare providers are pressed to deliver outcomes rapidly without compromising quality, initiatives like the Mayo Clinic Platform_Orchestrate not only represent a technological evolution but also a philosophical shift. An emphasis on collaboration over competition, shared knowledge, and transparency is vital for future breakthroughs in medicine. By fostering a sense of shared purpose among industry stakeholders, this program is well-positioned to unleash wave after wave of innovation cascading from research labs into clinics around the globe.

In this journey towards transforming healthcare delivery, Mayo Clinic honors its founding principles of patient-centered care. The institution’s commitment to deploying new technological innovations will undoubtedly contribute to a more efficient healthcare system that focuses on delivering superior outcomes for patients. The dual promises of safety and speed in bringing therapies to market are fundamental to the ethos of Mayo Clinic Platform_Orchestrate, and it establishes a higher standard for what biopharma and medical device partnerships can achieve in the 21st century.

As Mayo Clinic Platform_Orchestrate continues its mission, it serves not just as a beacon of hope for innovation in clinical research, but also as an affirmation of the potential that exists when world-class research meets collaborative spirit. This integration may well become the future blueprint of how healthcare providers and innovators collaborate to address urgent health challenges effectively and efficiently.

A new era in clinical development is dawning, one where speed meets precision. With Mayo Clinic Platform_Orchestrate at the forefront, the future holds unprecedented promise for patients, researchers, and the healthcare community at large.

Subject of Research: Clinical Development Acceleration
Article Title: Revolutionizing Therapies: Mayo Clinic Launches Platform_Orchestrate
News Publication Date: October 2023
Web References: https://www.mayoclinicplatform.org/orchestrate/
References: N/A
Image Credits: N/A

Keywords

Artificial intelligence, clinical research, healthcare innovation, biopharma, data-driven solutions.

At the core of this internship program lies the philosophy of biodesign—a methodology that bridges engineering principles with medical insights to develop impactful healthcare solutions. The research, as presented by Maloney, Page, Bielski, and their collaborators, underscores the necessity of equipping students with the skills and knowledge required not only to invent but to understand the regulatory and practical implications of medical device development. By immersing students in projects that require them to design, prototype, and iterate on medical devices, the program fosters a hands-on approach that is often lacking in traditional educational frameworks.

One of the most striking aspects of the program is its longitudinal nature, allowing students to engage in multiple phases of the design process over an extended period. This approach enhances retention of knowledge and skills, enabling participants to see the tangible outcomes of their efforts. Throughout the internship, students are faced with the reality of collaborating with healthcare professionals, patients, and industry stakeholders, allowing them to appreciate the multifaceted aspects of medical device innovation. Such interaction not only enriches their technical knowledge but also cultivates essential soft skills, such as communication, empathy, and teamwork.

The interdisciplinary dimension of the internship is equally pivotal. By incorporating students from various academic backgrounds, the program promotes diverse perspectives and creative problem-solving. For instance, pairing engineering students with those from fields such as design, business, and healthcare creates a dynamic environment where ideas can flourish. The collaborative efforts can lead to more holistic and user-centered medical devices, addressing not just the technical specifications, but also the end-user experience and market viability.

Funding and resource allocation play vital roles in the success of educational programs like this. The participants in the internship benefit from access to state-of-the-art facilities, mentorship from experienced professionals, and exposure to cutting-edge research and technologies. This environment not only inspires innovation but also instills confidence in students as they navigate the often-complex journey of bringing a medical device from concept to prototype. The financial backing behind such initiatives is crucial, as it reflects the commitment of educational institutions and industry partners to fostering the next generation of biomedical innovators.

Feedback mechanisms integrated into the program also enhance its effectiveness. By regularly assessing student experiences and outcomes, the program can adapt and evolve to meet both educational goals and market demands. Evaluations could include tracking the career paths of participants after completion, which serves to inform future cohorts and improve the overall internship experience. This data-driven approach embodies the proactive mindset necessary for success in a rapidly shifting technological landscape.

Moreover, the impact of this internship transcends academic boundaries, potentially influencing the broader biomedical engineering community. Returning alumni often share their insights and experiences, fostering a culture of continuous learning and improvement. This not only enhances the reputation of the program but also creates a network of professionals committed to advancing biomedical innovation. Such a community can be instrumental in driving forward new ideas and ensuring that the lessons learned are passed down to new generations.

As the research details the methodologies implemented, such as design thinking workshops, rapid prototyping sessions, and user testing scenarios, it becomes evident that each component is intricately designed to address the challenges faced in real-world medical contexts. Encouraging students to engage with actual healthcare problems ensures that they are not just learning for the sake of learning, but are instead actively contributing to solutions that could save lives. This practical application underscores the relevance of academic pursuits to the wider world.

It is also critical to acknowledge the ethical dimensions associated with medical device innovation. The program emphasizes ethical considerations, ensuring students are well-versed in the implications their designs carry. As the landscape of healthcare technology evolves, understanding the ethical ramifications of new devices becomes paramount. This focus fosters a generation of engineers who not only excel in technical skill but also prioritize the welfare of patients and the integrity of the medical field.

In summary, the longitudinal and interdisciplinary biodesign internship program represents a transformative approach to biomedical engineering education. By integrating practical experience with diverse knowledge sets, the program prepares students for the complexities of medical device innovation. As healthcare continues to evolve, the need for well-rounded, innovative thinkers is more critical than ever. With educational initiatives like this, the future of biomedical engineering looks promising, brimming with potential for breakthroughs that can significantly impact patient care and the healthcare system as a whole.

The collaboration between academia and industry within this program has the potential to yield significant advancements in the medical device sector. Creating partnerships between educational institutions and healthcare providers ensures that the technological innovations emerging from such programs are not only feasible but also meet the needs of the market. As such, these collaborative efforts are key to driving forward the innovations that will shape the future of healthcare.

In conclusion, as biomedical engineering students engage in this internship program, they find themselves at the intersection of education, innovation, and healthcare. This unique experience primes them to become not just engineers, but empathetic innovators who understand the real-world implications of their designs. As they navigate the complexities of medical device development, they carry the potential to influence positive change in the field, embodying the ethos of biodesign and addressing the pressing health challenges of our time.

Subject of Research: Longitudinal and Interdisciplinary Biodesign Internship Program for Biomedical Engineering Undergraduate Students

Article Title: A Longitudinal and Interdisciplinary Biodesign Internship Program for Biomedical Engineering Undergraduate Students Focused on Medical Device Innovation

Article References:

Maloney, L.M., Page, C., Bielski, M. et al. A Longitudinal and Interdisciplinary Biodesign Internship Program for Biomedical Engineering Undergraduate Students Focused on Medical Device Innovation.
Biomed Eng Education (2025). https://doi.org/10.1007/s43683-025-00174-w

Image Credits: AI Generated

DOI:

Keywords: Medical Device Innovation, Biodesign, Biomedical Engineering, Education, Interdisciplinary Collaboration, Practical Experience, Ethical Considerations, Healthcare Technology.